Skip to main content

Advertisement

Table 4 Risk of death from colorectal cancer according to BRAF mutation and by microsatellite instability status

From: Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study

  Entire cohort   Women   Men  
HR (95% CI) n(events) HR (95% CI) n(events) HR (95% CI) n(events)
BRAF status-MSS tumours (unadjusted)       
 Wild-type 1.00 384 (135) 1.00 194 (64) 1.00 190 (71)
 Mutated 2.36 (1.44–3.86) 29 (18) 1.73 (0.83–3.61) 16 (8) 3.46 (1.78–6.74) 13 (10)
BRAF status-MSI tumours (unadjusted)       
 Wild-type 1.00 28 (4) 1.00 16 (2) 1.00 12 (2)
 Mutated 1.68 (0.53–5.36) 43 (10) 2.15 (0.46–10.12) 31 (8) 1.03 (0.14–7.31) 12 (2)
BRAF status-MSS tumours (adjusted)       
 Wild-type 1.00 343 (118) 1.00 169 (54) 1.00 174 (64)
 Mutated 1.80 (0.98–3.28) 23 (14) 1.37 (0.56–3.35) 14 (7) 4.91 (1.99–12.12) 9 (7)
BRAF status-MSI tumours (adjusted)       
 Wild-type 1.00 27 (4) - - - -
 Mutated 3.24 (0.39–26.92) 40 (8) - - - -
  1. Adjusted analysis included age (continuous), sex, T stage (I-II, III, IV), N stage (0,1,2), M stage (0, 1), differentiation grade (high-intermediate vs. low and vascular invasion (+/−/unknown)) and KRAS mutation status (wild-type, codon 12 mutation, codon 13 mutation). One case with mutual KRAS codons 12 and 13 mutation was excluded from the adjusted analysis.